As AXL has been implicated in both long‐term resistance in AML and adaptive resistance in other cancers [30, 33], we hypothesized that targeting AXL could wholly or at least partially decrease the previously observed rapid rebound. This evidence concerns the gene AXL and acute myeloid leukemia.